De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Sopharma AD Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Ognian Donev

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salarisn/a
Dienstverband CEO24yrs
Eigendom CEO8.8%
Management gemiddelde ambtstermijngeen gegevens
Gemiddelde ambtstermijn bestuur9.8yrs

Recente managementupdates

Recent updates

Sopharma AD's (BUL:SFA) Problems Go Beyond Weak Profit

Sep 07
Sopharma AD's (BUL:SFA) Problems Go Beyond Weak Profit

Here's Why Sopharma AD (BUL:SFA) Can Manage Its Debt Responsibly

Jun 02
Here's Why Sopharma AD (BUL:SFA) Can Manage Its Debt Responsibly

Sopharma AD (BUL:SFA) Has A Somewhat Strained Balance Sheet

Apr 09
Sopharma AD (BUL:SFA) Has A Somewhat Strained Balance Sheet

Here's Why We Think Sopharma AD (BUL:3JR) Is Well Worth Watching

Feb 20
Here's Why We Think Sopharma AD (BUL:3JR) Is Well Worth Watching

How Many Sopharma AD (BUL:3JR) Shares Do Institutions Own?

Feb 05
How Many Sopharma AD (BUL:3JR) Shares Do Institutions Own?

Should You Rely On Sopharma AD's (BUL:3JR) Earnings Growth?

Jan 22
Should You Rely On Sopharma AD's (BUL:3JR) Earnings Growth?

Sopharma AD (BUL:3JR) Has A Somewhat Strained Balance Sheet

Jan 06
Sopharma AD (BUL:3JR) Has A Somewhat Strained Balance Sheet

Sopharma AD (BUL:3JR) Share Prices Have Dropped 25% In The Last Three Years

Dec 22
Sopharma AD (BUL:3JR) Share Prices Have Dropped 25% In The Last Three Years

Should Sopharma AD (BUL:3JR) Be Part Of Your Dividend Portfolio?

Dec 07
Should Sopharma AD (BUL:3JR) Be Part Of Your Dividend Portfolio?

Are Investors Undervaluing Sopharma AD (BUL:3JR) By 29%?

Nov 19
Are Investors Undervaluing Sopharma AD (BUL:3JR) By 29%?

Should Sopharma AD (BUL:3JR) Be Part Of Your Dividend Portfolio?

Jul 07
Should Sopharma AD (BUL:3JR) Be Part Of Your Dividend Portfolio?

CEO

Ognian Donev (67 yo)

24yrs

Tenure

лв723,162

Compensatie

Mr. Ognian Ivanov Donev, D.Sc. (Econ.), Ph D., serves as the Executive Chairman at Sopharma AD and Sopharma Trading AD and also served as Chief Executive Officer since September 2021 until November 2021. M...


Bestuursleden

NaamPositieTenureCompensatieEigendom
Ognian Donev
Chairman24yrsлв723.16k8.76%
BGN 86.3m
Vessela Stoeva
Deputy Chairmanno dataлв173.75k0.000090%
BGN 886.0
Ivan Badinski
Director6.2yrsлв252.59k0.0012%
BGN 12.0k
Alexandar Tchaoushev
Independent Director13.3yrsлв120.00k0.27%
BGN 2.6m
Bissera Lazarova
Director3.3yrsgeen gegevens0.021%
BGN 203.2k

9.8yrs

Gemiddelde duur

61yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van SFA wordt beschouwd als ervaren (gemiddelde ambtstermijn 9.8 jaar).